Back

TB-500 Peptide Evidence and Its 2026 HHS Compounding Status

By GetOPT Review Team · October 28, 2026 ·Part of our Peptides Guide

TB-500 is a synthetic seven-amino-acid fragment of thymosin beta-4, a 43-amino-acid protein. They are different substances. The U.S. Food and Drug Administration found no human clinical studies or case reports involving TB-500, so claims about TB-500 benefits, side effects, timing, and dosing cannot be confirmed from human evidence.1 Human research on full-length thymosin beta-4 does not establish that TB-500 produces the same effects. The U.S. Department of Health and Human Services (HHS) released a draft enforcement-discretion policy on October 28, 2026. It covers single-ingredient TB-500 acetate for subcutaneous or intramuscular injection, compounded by a state-licensed pharmacy or licensed physician on a patient-specific prescription.13 That policy is not an FDA approval, and a decision about your injury starts with your physician’s diagnosis.

The Difference Between TB-500 and Thymosin Beta-4

Thymosin beta-4 is a naturally occurring protein made from 43 amino acids. TB-500 is a synthetic fragment containing amino acids 17 to 23 of that protein, with an acetyl group attached to one end.1

The distinction changes how you should read the research. Human trials have tested full-length thymosin beta-4 through intravenous, topical, and ophthalmic routes. FDA found no comparable human trials of TB-500.1

FDA states that “thymosin beta-4 and TB-500 are not the same substance.” Its review also notes that websites often use the names interchangeably.1 A 2026 orthopaedic review reached a similar conclusion. TB-500 is frequently conflated with the full protein even though biologic and clinical equivalence have not been validated.2

Two 2026 reviews found no controlled human orthopaedic efficacy evidence for TB-500 or full-length thymosin beta-4.2,3 If you are considering TB-500 for an injury, your decision should start with the evidence for the molecule being offered. Research on the parent protein cannot be assigned to the fragment.

An injection can mask an undiagnosed injury. If pain or slow healing is the only signal you act on, the underlying injury can remain undefined. A diagnosis gives your physician a concrete condition to treat.

The head-to-head comparison of BPC-157 and TB-500 addresses the differences between those substances without treating them as interchangeable.

Is your TB-500 use being monitored?

Your Opt Health membership includes a lab panel, a physician's review, and follow-up testing.

See memberships

Human Research on the Full-Length Protein

Human research on full-length thymosin beta-4 includes safety trials and small efficacy trials. None of these studies tested TB-500.

Molecule TestedStudy TypePopulationResult
Synthetic full-length thymosin beta-4Randomized, placebo-controlled intravenous safety studyHealthy volunteersAdverse events were infrequent and mild or moderate. No efficacy outcome was measured.4
Recombinant full-length thymosin beta-4Randomized, double-blind phase 1 safety studyHealthy Chinese volunteersAdverse events were mild to moderate, with no serious adverse events or dose-limiting toxicities.5
Recombinant full-length thymosin beta-4Randomized, double-blind, placebo-controlled trial96 patients after ST-segment elevation myocardial infarction treated with percutaneous coronary interventionThe overall difference in infarct size at 90 days was not statistically significant. A subgroup treated earlier showed a reduction.6
Full-length thymosin beta-4 gelPhase 2, double-blind, placebo-controlled trialPeople with venous leg ulcersSafety was comparable to placebo. The authors described the healing findings as suggestive and exploratory.7
Full-length thymosin beta-4 eye dropsRandomized, placebo-controlled phase 2 trial72 people with dry eyeNeither primary endpoint differed from placebo.8
Full-length thymosin beta-4 eye dropsRandomized, placebo-controlled phase 3 trial18 people with neurotrophic keratopathyComplete healing occurred in 6 of 10 treated participants and 1 of 8 placebo participants. The result did not reach statistical significance.9
TB-500Cell scratch-wound experimentLaboratory cell modelTB-500 did not improve wound closure compared with control. One breakdown product produced a small effect.10

The two healthy-volunteer trials provide information about short-term exposure to full-length thymosin beta-4.4,5 They did not test whether the protein repairs a tendon, ligament, or muscle injury.

The heart, ulcer, and eye trials examined different medical conditions and routes of administration. Results were mixed. The overall heart-attack outcome missed statistical significance, the ulcer findings were exploratory, and both eye studies missed their primary statistical threshold.6-9

These trials can inform research on the full protein. They do not establish TB-500 benefits in people.

Inflammation and hormone markers can affect recovery, so a physician reads them as a pattern alongside your injury and symptoms. One marker alone does not set a treatment plan.

Laboratory and Animal Findings

Animal studies provide a biological reason for continued research on thymosin beta-4, but they do not prove that TB-500 heals human injuries.

Full-length thymosin beta-4 increased re-epithelialization of skin wounds in rats.11 Another study found that full-length thymosin beta-4 and a synthetic peptide containing its actin-binding region promoted skin repair in diabetic and aged mice.12 The synthetic peptide in that experiment was not acetylated TB-500.

The distinction becomes clearer in the laboratory study that tested TB-500 itself. TB-500 did not improve closure in a cell scratch-wound model compared with control.10 One of its breakdown products showed a small effect, but a cell experiment cannot establish injury healing in people.

FDA concluded that nonclinical pharmacological evidence was lacking to support TB-500 for wound healing.1 If your goal is recovery, start with the cause and extent of the injury rather than assigning a treatment based on animal research. The muscle recovery guide explains the basic factors that shape recovery.

A standard peptide protocol gives every injury the same answer. A measured plan starts with the diagnosed injury, your broader health pattern, and evidence for the treatment under consideration.

TB-500 Side Effects and Safety Evidence

TB-500 side effects have not been characterized in human clinical studies. FDA found no human case reports, pharmacokinetic studies, or clinical trials involving TB-500.1 Pharmacokinetics describes how a substance is absorbed, distributed, broken down, and removed from the body.

FDA also concluded that TB-500 was not physically and chemically well characterized. Its briefing identified possible immunogenicity from injectable peptides, including risks related to aggregation and peptide impurities.1 Immunogenicity means that a substance triggers an immune response.

These are possible risks identified from the substance and its proposed injectable routes. They are not observed rates of harm in human TB-500 trials because those trials do not exist.

The U.S. Department of Health and Human Services took a different view of the available safety record. HHS stated that FDA’s concerns were inferential rather than observed, the parent protein had a controlled human safety record across several routes, and the fragment was rapidly truncated in human serum.13 The parent-protein record remains different from direct TB-500 safety data. Until a TB-500 study in people exists, your physician weighs that gap against injury treatments that have human data.

The Federal Compounding Policy

The October 2026 HHS policy describes limited enforcement discretion for certain single-ingredient compounded peptide products. It includes TB-500 acetate for subcutaneous or intramuscular injectable dosage forms.13

Enforcement discretion is not FDA approval. The policy does not add TB-500 to the 503A bulks list, establish that it is safe or effective, or set a dose. The Federal Register notice describes the policy as a draft open for public comment and states that it is not binding on HHS or the public.14

The policy applies only when all listed conditions are met. Those conditions include:

  • TB-500 must meet the identity and route limits in the policy.
  • The bulk substance must come from a registered manufacturer and carry a valid certificate of analysis.
  • The certificate must address identity, purity, potency, and specified contaminants.
  • The compounder must report serious adverse events and product-quality problems.
  • The label must identify the product as compounded and state that it is not for resale.
  • The product must contain one active pharmaceutical ingredient.
  • Any co-packaged delivery device must be an FDA 510(k)-cleared syringe.
  • The prescription must be patient-specific and satisfy the other applicable requirements of the Federal Food, Drug, and Cosmetic Act.13

Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before marketing.13,14 The policy does not cover online research products. It also excludes blends, including a combined BPC-157 and TB-500 product.

The peptide policy overview explains the HHS route and the other five peptides named in the draft. If a clinician discusses compounded TB-500 with you, ask which pharmacy prepares it and how the product meets the policy conditions.

Anti-Doping Status and Product Identity

TB-500 is prohibited for athletes subject to anti-doping rules. FDA identifies TB-500 under section S2.3 of the World Anti-Doping Agency prohibited list.1 The U.S. Anti-Doping Agency also names TB-500 and thymosin beta-4 in its 2027 advisory.15

Product identity creates a separate problem. Laboratory analysis of internet products labeled “TB500” and “TB1000” found that their contents were not systematically consistent with their labels.16 A label therefore cannot confirm which molecule is inside the product.

If you compete under anti-doping rules, TB-500 is a prohibited substance for you. If you are considering an online research product, the available product-analysis evidence gives you no reliable basis for assuming that the label matches the contents.

Under the HHS conditions, the bulk TB-500 a pharmacy compounds from must carry a certificate of analysis covering identity, purity, potency, and contaminants.13

The Opt Take on TB-500

A slow-healing injury needs a diagnosis and a measured plan before an injection whose evidence comes from a different molecule is considered. Human research on full-length thymosin beta-4 cannot establish what TB-500 will do in your body.

A physician should interpret the evidence against your injury, symptoms, health history, current medications, and goals before a peptide enters the conversation. TB-500 does not have human efficacy or safety data that can support a standard protocol.

At Opt Health, we start with comprehensive labs covering more than 55 biomarkers. A physician reviews the results with you, builds a personalized plan, and reassesses your progress every three to four months. Treatment depends on your full pattern rather than a peptide claim or one isolated number.

TB-500 should not be treated as a standard recovery kit. Your physician can explain where the evidence ends, whether another cause needs attention, and which monitored options fit your health profile.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

No peptide in the cited evidence can be called the best option for human injury healing. Two 2026 orthopaedic reviews found no controlled human orthopaedic efficacy evidence for BPC-157, full-length thymosin beta-4, or TB-500.2,3

Your first step is a clear diagnosis of the injury and a physician-led recovery plan. A peptide should not substitute for finding out which tissue is injured and which treatment has human evidence for that condition.

There is no controlled human evidence in the cited sources establishing the safety or efficacy of the combination. The HHS enforcement-discretion policy covers single-ingredient products, so a BPC-157 and TB-500 blend falls outside that policy.13

The Wolverine Stack overview explains the combination and the limits of the available evidence. If you are considering both substances, discuss the combination itself with a prescriber rather than assuming that evidence for either ingredient applies to the blend.

No human study has established when TB-500 starts working. FDA found no human clinical trials, case reports, or pharmacokinetic studies involving TB-500.1

Timelines drawn from seller claims, animal experiments, or full-length thymosin beta-4 trials do not establish a human onset time for TB-500. Your physician should set expectations from the diagnosed condition and the treatment being used.

No evidence-based daily amount can be given because no human dosing study of TB-500 exists. FDA found no human pharmacokinetic or clinical studies that could support a regimen.1

Do not set an injectable peptide regimen from an online schedule. Any prescription regimen is set by a prescriber after reviewing your health history, medications, treatment goal, and the limits of the evidence.

A slow-healing injury calls for a diagnosis, a review of your health pattern, and a plan that can be reassessed over time. An Opt Health membership pairs a 55+ biomarker panel with a 1:1 physician review and follow-up testing every three to four months.

References

  1. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: TB-500. May 15, 2026. https://www.fda.gov/media/193349/download
  2. Tham A, et al. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg. 2026. https://pubmed.ncbi.nlm.nih.gov/42937313/
  3. Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223-229. https://pubmed.ncbi.nlm.nih.gov/41476424/
  4. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. https://pubmed.ncbi.nlm.nih.gov/20536472/
  5. Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. https://pubmed.ncbi.nlm.nih.gov/34346165/
  6. Zhang Y, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758. https://pubmed.ncbi.nlm.nih.gov/41229390/
  7. Guarnera G, et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-212. https://pubmed.ncbi.nlm.nih.gov/20536470/
  8. Sosne G, et al. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-884. https://pubmed.ncbi.nlm.nih.gov/26056426/
  9. Sosne G, et al. 0.1% RGN-259 (Thymosin ß4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial. Int J Mol Sci. 2022. https://pubmed.ncbi.nlm.nih.gov/36613994/
  10. Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B. 2024. https://pubmed.ncbi.nlm.nih.gov/38382158/
  11. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
  12. Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. https://pubmed.ncbi.nlm.nih.gov/12581423/
  13. U.S. Department of Health and Human Services. HHS enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A and Appendix B. October 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  14. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Federal Register. 2026-22192. https://www.federalregister.gov/d/2026-22192
  15. U.S. Anti-Doping Agency. Athlete advisory: 2027 prohibited list. https://www.usada.org/spirit-of-sport/athlete-advisory-2027-prohibited-list/
  16. Delcourt V, et al. TB500/TB1000 and SGF1000: a scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458-464. https://pubmed.ncbi.nlm.nih.gov/36482504/

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.

This article is part of our guide to peptides. See how physician-guided peptide therapy works at Opt Health.

You might also like

Start Today

Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.

Start Today